Nektar Therapeutics (NKTR) Tops Q3 EPS by 185c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $71.90 --0%
Revenue Growth %: -7.1%
Financial Fact:
Other income (expense), net: 332K
Today's EPS Names:
CCEL, SLP, TMQ, More
Revenue Growth %: -7.1%
Financial Fact:
Other income (expense), net: 332K
Today's EPS Names:
CCEL, SLP, TMQ, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of $1.85. Revenue for the quarter came in at $11.79 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho Upgrades Five Below (FIVE) to Outperform, 'we believe the pendulum has swung too far on valuation'
- CLSA Reiterates High-Conviction Outperform (1) Rating on Tencent Holdings (700:HK) (TCEHY)
- Mizuho Downgrades Tractor Supply Company (TSCO) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
